Wall Street is waking up to the fact that legal cannabis is quickly going mainstream.
After all, a $3.8 billion investment is the kind of move that makes big waves.
Of course, this is something we've been talking about for close to two years. And by being way ahead of the curve, you folks and my Nova-X Report members have had the chance to score some pretty sizzling gains.
Now then, there's no question the Aug. 15 news that Constellation Brands Inc. (NYSE: STZ) is spending close to $4 billion to take a 38% stake in the Canadian cannabis firm Canopy Growth Corp. (Nasdaq: CGC) was a game changer.
Many cannabis stocks have rallied on the news – and I hope you were in on some of that.
But there's an element to the deal that almost no one else is taking about.
You see, I think this mega investment marks the beginning of whole new financial trend.
One that will mean big bucks for cannabis investors.
You won't want to miss this…
Trump's Green Light
Let me show you what I'm talking about…
Despite massive growth in the space and a majority of states making medical marijuana legal, cannabis stocks had been under pressure for several months.
That's largely because in early January, U.S. Attorney General Jeff Sessions sparked a sell-off in the sector. A longtime cannabis critic, Sessions said he retained the right to crack down on states that had made marijuana legal.
Sessions cast doubt on the sector because marijuana remains illegal under federal law – despite the fact that 30 states and the District of Columbia have legalized some form of cannabis use.
Of course, we now know the odds of a federal crackdown are highly unlikely. Even Sessions' boss, U.S. President Donald Trump, supports a bipartisan compromise under which states could make marijuana use legal without interference from the federal government.
Known as the STATES Act, the legislation would allow each state to determine for itself the best approach to marijuana within its borders – without fear of a U.S. Department of Justice crackdown.
Because it draws on states' rights under the 10th Amendment to the U.S. Constitution, the bill has gained approval from conservatives – and the the bill has wide support in both the House and Senate.
While that's a great backdrop for the emerging cannabis sector, there's nothing quite like a multibillion-dollar deal to get investors excited about huge gains ahead.
That's why Constellation's new pact with Canopy is so vital. See, Constellation is the global beverage giant behind Corona beer, Robert Mondavi wines, Svedka vodka, and many other well-known brands.
And it marks the start of the great marijuana sector buyout trend – in which big consumer products companies will spend the next few years acquiring cannabis companies.
But here's why this deal is even more important than it sounds…
About the Author
Michael A. Robinson is a 36-year Silicon Valley veteran and one of the top tech and biotech financial analysts working today. That's because, as a consultant, senior adviser, and board member for Silicon Valley venture capital firms, Michael enjoys privileged access to pioneering CEOs, scientists, and high-profile players. And he brings this entire world of Silicon Valley "insiders" right to you...
- He was one of five people involved in early meetings for the $160 billion "cloud" computing phenomenon.
- He was there as Lee Iacocca and Roger Smith, the CEOs of Chrysler and GM, led the robotics revolution that saved the U.S. automotive industry.
- As cyber-security was becoming a focus of national security, Michael was with Dave DeWalt, the CEO of McAfee, right before Intel acquired his company for $7.8 billion.
This all means the entire world is constantly seeking Michael's insight.
In addition to being a regular guest and panelist on CNBC and Fox Business, he is also a Pulitzer Prize-nominated writer and reporter. His first book Overdrawn: The Bailout of American Savings warned people about the coming financial collapse - years before the word "bailout" became a household word.
Silicon Valley defense publications vie for his analysis. He's worked for Defense Media Network and Signal Magazine, as well as The New York Times, American Enterprise, and The Wall Street Journal.
And even with decades of experience, Michael believes there has never been a moment in time quite like this.
Right now, medical breakthroughs that once took years to develop are moving at a record speed. And that means we are going to see highly lucrative biotech investment opportunities come in fast and furious.
To help you navigate the historic opportunity in biotech, Michael launched the Bio-Tech Profit Alliance.
His other publications include: Strategic Tech Investor, The Nova-X Report, Bio-Technology Profit Alliance and Nexus-9 Network.